The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells
Open accessAbstract
Transplanted donor lymphocytes infused during hematopoietic stem cell transplantation (HSCT) have been shown to cure patients with hematological malignancies. However, less is known about the effects of HSCT on metastatic solid tumors. Thus, a better understanding of the immune cells and their target antigens that mediate tumor regression is urgently needed to develop more effective HSCT approaches for solid tumors. Here we report regression of metastatic renal cell carcinoma (RCC) in patients following nonmyeloablative HSCT consistent with a graft-versus-tumor effect. We detected RCC-reactive donor-derived CD8(+) T cells in the blood of patients following nonmyeloablative HSCT. Using cDNA expression cloning, we identified a 10-mer peptide (CT-RCC-1) as a target antigen of RCC-specific CD8(+) T cells. The genes encoding this antigen were found to be derived from human endogenous retrovirus (HERV) type E and were expressed in RCC cell lines and fresh RCC tissue but not in normal kidney or other tissues. We believe this to be the first solid tumor antigen identified using allogeneic T cells from a patient undergoing HSCT. These data suggest that HERV-E is activated in RCC and that it encodes an overexpressed immunogenic antigen, therefore providing a potential target for cellular immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Endogenous retroviruses in the human genome sequence.
(2001) · Genome biology · doi:10.1186/gb-2001-2-6-reviews1017 · Cited by 317
Expression of Human Endogenous Retrovirus K in Melanomas and Melanoma Cell Lines
Büscher, K., Trefzer, U., Hofmann, M., Sterry, W., Kurth, R., & Denner, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2983 · Cited by 249
Cited by
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Braun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0839-y · Cited by 992
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Kolb, H.-J. (2008) · Blood · doi:10.1182/blood-2008-03-077974 · Cited by 582
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
Braun, D. A., Street, K., Burke, K. P., Cookmeyer, D. L., Denize, T., Pedersen, C. B., Gohil, S. H., Schindler, N., Pomerance, L., Hirsch, L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.013 · Cited by 504
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449
“In one, a patient with metastatic renal cell cancer (RCC) who experienced a complete tumor regression following hematopoietic stem cell transplantation was found to have circulating donor T cells that recognized an HERV-E-derived peptide (Takahashi et al., 2008).”
BackgroundEpigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity
Griffin, G. K., Wu, J., Iracheta-Vellve, A., Patti, J. C., Hsu, J., Davis, T., Dele-Oni, D., Du, P. P., Halawi, A. G., Ishizuka, J. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03520-4 · Cited by 370
Lamers, C. H. J., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., & Gratama, J. W. (2011) · Blood · doi:10.1182/blood-2010-07-294520 · Cited by 368
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356
Alternative tumour-specific antigens
Smith, C. C., Selitsky, S. R., Chai, S., Armistead, P. M., Vincent, B. G., & Serody, J. S. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0162-4 · Cited by 351
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 323
Classification and characterization of human endogenous retroviruses; mosaic forms are common
Vargiu, L., Rodriguez-Tomé, P., Sperber, G. O., Cadeddu, M., Grandi, N., Blikstad, V., Tramontano, E., & Blomberg, J. (2016) · Retrovirology · doi:10.1186/s12977-015-0232-y · Cited by 315
Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
Smith, C. C., Beckermann, K. E., Bortone, D. S., De Cubas, A. A., Bixby, L. M., Lee, S. J., Panda, A., Ganesan, S., Bhanot, G., Wallen, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121476 · Cited by 303
Kong, Y., Rose, C. M., Cass, A. A., Williams, A. G., Darwish, M., Lianoglou, S., Haverty, P. M., Tong, A.-J., Blanchette, C., Albert, M. L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13035-2 · Cited by 285
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Au, L., Hatipoglu, E., Robert de Massy, M., Litchfield, K., Beattie, G., Rowan, A., Schnidrig, D., Thompson, R., Byrne, F., Horswell, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.001 · Cited by 260
Oldham, K. A., Parsonage, G., Bhatt, R. I., Wallace, D. M. A., Deshmukh, N., Chaudhri, S., Adams, D. H., & Lee, S. P. (2012) · European Urology · doi:10.1016/j.eururo.2011.10.035 · Cited by 104
HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy
Jiang, Q., Braun, D. A., Clauser, K. R., Ramesh, V., Shirole, N. H., Duke-Cohan, J. E., Nabilsi, N., Kramer, N. J., Forman, C., Lippincott, I. E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.01.046 · Cited by 68
Self-citationYoung, G. R., Ploquin, M. J.-Y., Eksmond, U., Wadwa, M., Stoye, J. P., & Kassiotis, G. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002709 · Cited by 56
Metadata
- Authors
- Takahashi, Y., Harashima, N., Kajigaya, S., Yokoyama, H., Cherkasova, E., McCoy, J. P., Hanada, K.-I., Mena, O., Kurlander, R., Abdul, T., Srinivasan, R., Lundqvist, A., Malinzak, E., Geller, N., Lerman, M. I., & Childs, R. W.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-02-01
- Volume
- 118
- Issue
- 3
- Pages
- 1099-109
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2126329119
- Cited by
- 185
- References
- 3
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.